C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

PURPOSE: Findings from the human epidermal growth factor receptor 2 (HER2) –positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Perez, Edith A., Jenkins, Robert B., Dueck, Amylou C., Wiktor, Anne E., Bedroske, Patrick P., Anderson, S. Keith, Ketterling, Rhett P., Sukov, William R., Kanehira, Kazunori, Chen, Beiyun, Geiger, Xochiquetzal J., Andorfer, Cathy A., McCullough, Ann E., Davidson, Nancy E., Martino, Silvana, Sledge, George W., Kaufman, Peter A., Kutteh, Leila A., Gralow, Julie R., Harris, Lyndsay N., Ingle, James N., Lingle, Wilma L., Reinholz, Monica M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2011
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3056653/
https://ncbi.nlm.nih.gov/pubmed/21245420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.30.2125
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados